Abstract
ROLE OF VILDAGLIPTIN- DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - AN OVERVIEW

Revathi Pitchaipillai*, Bhuvaneswari Shanmugasundaram, Sarojini Kaliyaperumal, Jeyaseelan Senthinath and Manickavasagam Subramania Pillai

ABSTRACT

Diabetes is a condition in which the body does not produce or respond to insulin, a hormone that regulates the level of sugar in the blood. It is characterized by abnormally high levels of glucose in the blood. They are classified into three categories Type 1 Diabetes mellitus (DM), Type 2 Diabetes mellitus (DM) and Gestational diabetes. The prevalence of T2DM is increasing rapidly and plays a vital role in the genesis of the pathophysiological events. Oral hypoglycemic agents are used in the treatment of T2DM and they have their own limitations.
Newer drugs have been invented for the treatment of T2DM. Dipeptidyl peptidase 4 (DPP-4) inhibitors plays an important role in the treatment of T2DM. There are six DPP-4 inhibitor identified (Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin and teneligliptin). Vildagliptin is a second DPP-4 inhibitor approved by US FDA in February 2007. It is an orally active, potent, and selective DPP-4 inhibitor shown to be effective and well tolerated by patients with T2DM. It is rapidly and well absorbed with an oral bioavailability of 85 %. It is effective either as monotherapy or in combination with other antidiabetic agents. It has got lower incidence of hypoglycemic symptoms when used as a monotherapy or combination therapy with other oral hypoglycemic drugs. Vildagliptin once daily or twice daily is found to be an effective, safety and well tolerated DPP-4 inhibitor as monotherapy or combination therapy with oral hypoglemic agents (OHA) or insulin in the treatment of T2DM patients.

Keywords: Vildagliptin, diabetes mellitus, therapeutic management.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: MAY ISSUE PUBLISHED

    MAY 2024 Issue has been successfully launched on 1 MAY 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT